BG107762A - Радиофармацевтични средства за диагностициране болестта на алцхаймер - Google Patents

Радиофармацевтични средства за диагностициране болестта на алцхаймер

Info

Publication number
BG107762A
BG107762A BG107762A BG10776203A BG107762A BG 107762 A BG107762 A BG 107762A BG 107762 A BG107762 A BG 107762A BG 10776203 A BG10776203 A BG 10776203A BG 107762 A BG107762 A BG 107762A
Authority
BG
Bulgaria
Prior art keywords
radiopharmaceuticals
alzheimer
disease diagnostics
disease
diagnostics
Prior art date
Application number
BG107762A
Other languages
Bulgarian (bg)
English (en)
Inventor
Christoph-Steph Hilger
Bernd Johannsen
Jorg Steinbach
Peter Maeding
Meredith Halks-Miller
Richard Horuk
Harald Dinter
Raju Mohan
Joseph E. Hesselgesser
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of BG107762A publication Critical patent/BG107762A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG107762A 2000-11-06 2003-04-25 Радиофармацевтични средства за диагностициране болестта на алцхаймер BG107762A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24629900P 2000-11-06 2000-11-06
PCT/EP2001/012607 WO2002036581A1 (en) 2000-11-06 2001-11-01 Radiopharmaceuticals for diagnosing alzheimer's disease

Publications (1)

Publication Number Publication Date
BG107762A true BG107762A (bg) 2004-03-31

Family

ID=22930075

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107762A BG107762A (bg) 2000-11-06 2003-04-25 Радиофармацевтични средства за диагностициране болестта на алцхаймер

Country Status (29)

Country Link
US (2) US6676926B2 (pl)
EP (1) EP1332138B1 (pl)
JP (1) JP4234425B2 (pl)
KR (1) KR20030045167A (pl)
CN (1) CN1473158A (pl)
AR (1) AR035366A1 (pl)
AT (1) ATE314354T1 (pl)
AU (2) AU1403402A (pl)
BG (1) BG107762A (pl)
BR (1) BR0115150A (pl)
CA (1) CA2424598A1 (pl)
DE (1) DE60116365T2 (pl)
EA (1) EA006199B1 (pl)
EE (1) EE200300216A (pl)
HR (1) HRP20030459A2 (pl)
HU (1) HUP0301710A3 (pl)
IL (1) IL155191A0 (pl)
JO (1) JO2207B1 (pl)
MX (1) MXPA03003759A (pl)
NO (1) NO20032007L (pl)
NZ (1) NZ525303A (pl)
PE (1) PE20020531A1 (pl)
PL (1) PL361631A1 (pl)
SK (1) SK287495B6 (pl)
TW (1) TWI238820B (pl)
UY (1) UY27003A1 (pl)
WO (1) WO2002036581A1 (pl)
YU (1) YU33203A (pl)
ZA (1) ZA200304409B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
OA12670A (en) 2001-10-22 2006-06-20 Pfizer Prod Inc Piperazine derivatives with ccr1 receptor antagonist activity.
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
WO2004100490A2 (de) * 2003-05-07 2004-11-18 Schering Ag Vorrichtung und verfahren zum nucleophilen fluorieren
EP2388017B1 (en) * 2004-02-24 2014-12-24 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
KR100778888B1 (ko) * 2005-11-29 2007-11-28 재단법인서울대학교산학협력재단 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물
WO2008030604A2 (en) 2006-09-08 2008-03-13 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
CA2663115C (en) 2006-09-08 2015-04-28 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
CN101563305A (zh) * 2006-12-21 2009-10-21 哈默史密斯网上成像有限公司 放射性标记方法
JP2011502966A (ja) * 2007-10-31 2011-01-27 アルセレス ファーマシューティカルズ， インコーポレイテッド ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法
EP3231804B1 (en) 2008-03-21 2021-03-03 The General Hospital Corporation Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
EP2161256A1 (en) * 2008-09-08 2010-03-10 Atomic Energy Council - Institute of Nuclear Energy Research Compound containing carboxylate ester and N2S2 ligand bi-functional groups and manufacturing method thereof
EP2163541A1 (en) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazine derivatives for binding and imaging amyloid plaques and their use
WO2011041470A2 (en) * 2009-09-30 2011-04-07 Mallinckrodt Inc. Sustained-release opiate and opiate derivative compositions
TW201201846A (en) * 2010-02-08 2012-01-16 Bayer Schering Pharma Ag Iodo precursor for a PET imaging agent of amyloid plaques
WO2011110511A1 (en) * 2010-03-11 2011-09-15 Bayer Pharma Aktiengesellschaft Spect imaging agents of amyloid plaques
WO2012159107A1 (en) 2011-05-19 2012-11-22 Rhode Island Hospital Inhibition of renal fibrosis
EP4321165A3 (en) 2013-12-27 2024-08-21 National University Corporation Tokyo Medical and Dental University Method for diagnosis of alzheimer's disease and frontotemporal lobar degeneration, diagnostic agent, therapeutic agent, and screening method for said agents
MX382156B (es) * 2015-08-28 2025-03-13 Chdi Foundation Inc Sondas para formar imagenes de proteina de huntingtina.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU654013B2 (en) 1991-03-13 1994-10-20 Regents Of The University Of Minnesota 2-hydroxy-3(4-iodophenyl)-1-(4-phenylpiperidinyl) propane
EP0524146A1 (de) 1991-07-19 1993-01-20 Ciba-Geigy Ag Aminosubstituierte Piperazinderivate
GB9413772D0 (en) 1994-07-08 1994-08-24 Wyeth John & Brother Ltd 5-HT1A ligands
AU2680797A (en) * 1996-04-24 1997-11-12 Emory University Halogenated naphthyl methoxy piperidines for mapping serotonin transporter sites
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
BR0009338A (pt) 1999-03-26 2001-12-26 Astrazeneca Ab Composto, processo para a preparação do mesmo,composição farmacêutica, processo para apreparação da mesma, uso de um composto, e,método de tratamento de uma doençainflamatória em um paciente sofrendo ou em riscode dita doença
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer

Also Published As

Publication number Publication date
NO20032007D0 (no) 2003-05-05
PE20020531A1 (es) 2002-06-15
AR035366A1 (es) 2004-05-12
UY27003A1 (es) 2002-07-31
WO2002036581A1 (en) 2002-05-10
SK5472003A3 (en) 2003-10-07
CA2424598A1 (en) 2002-05-10
US6872381B1 (en) 2005-03-29
NZ525303A (en) 2004-10-29
JO2207B1 (en) 2004-10-07
EA200300507A1 (ru) 2003-12-25
NO20032007L (no) 2003-07-02
JP4234425B2 (ja) 2009-03-04
PL361631A1 (pl) 2004-10-04
HUP0301710A3 (en) 2007-03-28
KR20030045167A (ko) 2003-06-09
AU1403402A (en) 2002-05-15
MXPA03003759A (es) 2003-07-28
AU2002214034B2 (en) 2006-01-05
DE60116365T2 (de) 2006-08-24
BR0115150A (pt) 2003-12-30
ZA200304409B (en) 2004-09-06
YU33203A (sh) 2006-05-25
US6676926B2 (en) 2004-01-13
EA006199B1 (ru) 2005-10-27
HUP0301710A2 (hu) 2003-11-28
HRP20030459A2 (en) 2005-04-30
ATE314354T1 (de) 2006-01-15
JP2004513123A (ja) 2004-04-30
EP1332138A1 (en) 2003-08-06
EE200300216A (et) 2003-08-15
TWI238820B (en) 2005-09-01
EP1332138B1 (en) 2005-12-28
SK287495B6 (sk) 2010-12-07
IL155191A0 (en) 2003-11-23
CN1473158A (zh) 2004-02-04
DE60116365D1 (de) 2006-02-02
US20020131932A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
BG107762A (bg) Радиофармацевтични средства за диагностициране болестта на алцхаймер
LTPA2015001I1 (lt) Tioflavino dariniai ir jų panaudojimas Alzhaimerio ligos diagnostikai ir terapijai
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
TW200518753A (en) Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
EA200401114A2 (ru) Замещённые гидроксиэтиламины
GEP20053655B (en) 5-HT Receptor Ligands and Uses Thereof
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
GB0108592D0 (en) Therapeutic agents
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
BRPI0409634A (pt) ligantes de receptores de canabinóides e utilização destes
ES2248356T3 (es) Compuestos para tratar la enfermedad de alzheimer.
DE60037139D1 (de) Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha-synuclein fibril krankheiten
DK0975595T3 (da) Kokainanaloger
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
EP1689713A4 (en) BENZYL ETHER AND BENZYLAMINE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
ES2147616T3 (es) Derivados de piperidina con actividad antagonista del paf.
ATE403428T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
PT1562954E (pt) Antagonistas de ccr1 para o tratamento da doenca desmielinzante inflamatoria i.a.
TR200800691T2 (tr) Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi.
EP1896005A4 (en) SYNERGISTIC PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF BETA AMYLOID PROTEIN-INDUCED DISEASES WITH SALBEI AND ROSMARIN COMPOUNDS
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
ATE491474T1 (de) Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists
TH65073A (th) รังสีเภสัชกรรมสำหรับการวินิจฉัยโรคแอลไซเมอร์